Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-Guggulsterone SCHEMBL7860363 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL13327483 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL12153588 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL13304392 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL14193742 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL1650063 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL258031 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL177528 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL177786 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL12858540 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1035 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734960-A1 | STEROL ANALOGS IN LIPID NANOPARTICLE FORMULATIONS | Sanofi Pasteur Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4714440-A2 | A HEALING HERBAL-MINERAL COMPOSITION WITH ENHANCED EFFECTS | Kurek, Janusz (PL) | 2026-03-25 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250152605-A1 | METHOD AND DRUG FOR TREATING NEURONAL CEROID LIPOFUSCINOSIS | TSINGHUA UNIVERSITY (CN) | 2025-05-15 | — | — | US | claimed |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-04-24 | — | — | US | claimed |
| US-12194068-B2 | Dietary supplement composition for treating and managing acne | CODEX LABS CORPORATION (US) | 2025-01-14 | — | — | US | claimed |
| WO-2025003760-A1 | STEROL ANALOGS IN LIPID NANOPARTICLE FORMULATIONS | SANOFI (FR) | 2025-01-02 | — | — | WO | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240277789-A1 | DIETARY SUPPLEMENT COMPOSITION FOR TREATING AND MANAGING ACNE | CODEX LABS CORPORATION | 2024-08-22 | — | — | US | claimed |
| US-20240277786-A1 | DIETARY SUPPLEMENT COMPOSITION FOR TREATING AND MANAGING ACNE | CODEX LABS CORP (US) | 2024-08-22 | — | — | US | claimed |
| WO-2006017211-A1 | GUGGULSTERONE AS AN INHIBITOR OF NUCLEAR FACTOR-KB AND IKBALPHA KINASE ACTIVATION | RESEARCH DEVELOPMENT FOUNDATION (US) | 2006-02-16 | — | — | WO | claimed |
| US-20060019907-A1 | Guggulsterone: an inhibitor of nuclear factor - kappaB and IkappaBalpha kinase activation and uses thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2006-01-26 | — | — | US | claimed |
| US-20050288244-A1 | Oligonucleotides comprising a C5-modified pyrimidine | ALNYLAM PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | claimed |
| WO-2005089316-A2 | TREATMENT OF FIBROSIS USING FXR LIGANDS | INTERCEPT PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050080023-A1 | Osteoclastogenesis inhibitors and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-04-14 | — | — | US | claimed |
| US-20050025844-A1 | Weight control compositions and methods | SAN CORPORATION | 2005-02-03 | — | — | US | claimed |
| EP-0997149-B1 | Compositions comprising guggul extract and phosphate salts | PROLAB NUTRITION INC (US) | 2002-03-20 | — | — | EP | claimed |
| US-6120779-A | MOISTURIZING | SOMA TECHNOLOGIES (US) | 2000-09-19 | — | — | US | claimed |
| EP-0513671-B1 | Commiphora mukul extracts and therapeutical applications thereof | INDENA SPA (IT) | 2000-02-09 | — | — | EP | claimed |
| US-5273747-A | Sovent extract process to obtain Guggulsterones and Guggulsterols | INDENA S.P.A. (IT) | 1993-12-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152605-A1 | METHOD AND DRUG FOR TREATING NEURONAL CEROID LIPOFUSCINOSIS | CLN6, KEAP1, NFE2L2 | SMN1; SMN2 254/4885HSD17B10 2408/4885ALDH1A1 1956/4885 |
| US-20050288244-A1 | Oligonucleotides comprising a C5-modified pyrimidine | DUT, TYMP, DPYD | SMN1; SMN2 3242/4885HSD17B10 1120/4885ALDH1A1 987/4885 |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | PIM3, PIM1, PIM2 | SMN1; SMN2 3846/4885HSD17B10 3124/4885ALDH1A1 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.